, Twitter: @WFPeacock.
INTRODUCTION Background
Atrial fibrillation is the most common cardiac arrhythmia [1] [2] [3] and is associated with significant morbidity and mortality related to stroke and thromboembolism. 2 The prevalence of atrial fibrillation is estimated to be 0.1% in persons younger than 55 years and as high as 10% in those older than 85 years. 1, 3 Incidence of atrial fibrillation is expected to increase as the population ages and the occurrence of risk factors increases. [1] [2] [3] The most devastating and potentially fatal consequence of atrial fibrillation is ischemic stroke. 1, 3, 4 Strokes in atrial fibrillation patients are often more severe than other types of stroke, with more instances of disability or death. [5] [6] [7] Assessing the atrial fibrillation stroke risk depends on the evaluation of patient characteristics, comorbidities, and clinical features. 1, 2, 8 Older age and history of stroke, transient ischemic attack, or thromboembolism are the strongest independent predictors of stroke in atrial fibrillation patients. 1, 2, 5 Additionally, diabetes, female sex, vascular disease, and congestive heart failure are associated with elevated stroke risk among persons with atrial fibrillation.
Editor's Capsule Summary
What is already known on this topic The decision to use anticoagulants in atrial fibrillation is based on an assessment of the competing risks of stroke and excessive bleeding.
What question this study addressed Does the CHA 2 DS 2 -VASc (congestive heart failure/ left ventricular dysfunction, hypertension, 75 years, diabetes mellitus, previous stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65 to 74 years, sex female) validated stroke risk assessment tool for nonvalvular atrial fibrillation correlate with major bleeding in patients receiving rivaroxaban?
What this study adds to our knowledge In a Department of Defense data set with 44,793 patients, increasing stroke risk score correlated with more frequent major bleeding, especially in patients with high vascular disease components to the score.
How this is relevant to clinical practice
Expect more patients to seek emergency care for major bleeding while receiving rivaroxaban for nonvalvular atrial fibrillation as stroke risk increases.
Society of Cardiology, 8 the American College of Cardiology and American Heart Association, 9 and the National Institute for Health and Care Excellence 10 recommend the use of CHA 2 DS 2 -VASc (congestive heart failure/left ventricular dysfunction, hypertension, 75 years, diabetes mellitus, previous stroke or transient ischemic attack or thromboembolism, vascular disease, aged 65 to 74 years, sex female) 11 as the preferred risk-scoring method to gauge stroke risk in atrial fibrillation patients. 1, 12 Using stroke risk scores allows targeted interventions to aid in the prevention of thrombotic events, namely, through the use of oral anticoagulants. 1, 9 Clinical studies provide evidence of therapeutic options at a population level. However, in clinical practice, treatment options must be considered from the perspective of the individual patient and require strategic personalization that considers the unique constellation of risks and benefits, of which few are typically represented in clinical trials.
With the availability of anticoagulation that does not require heparin bridging, consequent to medications that are effective within 2 hours, the need for hospitalization for anticoagulation is rapidly declining. Thus, in selected patients the emergency physician will need to choose between a hospital admission of little benefit (besides administration of a daily pill) or discharge with the patient receiving oral anticoagulation. Knowledge of the risks and benefits of oral anticoagulants is becoming critical. In treating atrial fibrillation patients at risk for stroke, clinicians must determine whether the net clinical benefit from anticoagulation therapy outweighs its risk, namely, bleeding.
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Importance
Clinicians must weigh many factors when deciding whether a patient should receive anticoagulation therapy. Assessing the risk for any given patient requires a personalized assessment of his or her risk of stroke without therapy versus the risk of bleeding with therapy. CHA 2 DS 2 -VASc scores have been proven to quantify stroke risk [8] [9] [10] [11] [12] ; these scores may also have a relationship with bleeding risk. Understanding the relationship between CHA 2 DS 2 -VASc scores and the incidence of major bleeding may provide another valuable tool in the clinical decisionmaking process.
Goals of This Investigation
The current evaluation was derived from an ongoing, 5-year pharmacovigilance study, designed to provide longitudinal safety data by actively obtaining information associated with rivaroxaban use in the postapproval setting, complementary to the clinical trial data and that being collected by the spontaneous adverse event reporting process. Our objective for this analysis was to examine the relationship between CHA 2 DS 2 -VASc scores and the incidence of nontrauma-related major bleeding in rivaroxaban users with nonvalvular atrial fibrillation.
MATERIALS AND METHODS Study Design
This observational study used a retrospectively assembled cohort of patients diagnosed with nonvalvular atrial fibrillation. Within this population, patients who were exposed to rivaroxaban were included in the study analyses.
Selection of Participants
The patient population for this analysis was derived from the US Department of Defense electronic medical records system. The Department of Defense Military Health System covers military service members and their families and represents one of the largest US health systems, with nearly 10 million active patients. 13 The system is not linked with data streams from Veterans Affairs because it 542 Annals of Emergency Medicine Volume 69, no. 5 : May 2017 and the Military Health System are separate entities; therefore, this study population does not contain data from the Veterans Affairs patient population.
The Military Health System population has a relatively high representation of elderly, with patients older than 65 years making up more than 20% of the total 14 compared with 13% of the overall US population. 15 The Military Health System databases consist of longitudinal electronic medical records that are continually updated and contain administrative, pharmacy, laboratory, and clinical data. Inpatient and outpatient data are integrated, which ensures robust capture of medical encounters, including major bleeding events, along with associated pharmacy data. As described previously, the Department of Defense health care system is paperless, and all patient-level medical information and clinical data are kept in one electronic format. Incoming records are checked against a set of minimum standards for quality to ensure the integrity of the data, and duplicate records are removed before analysis. 
Study Interval and Patient Eligibility
This study analyzed data from the 2.5-year observation period of January 1, 2013 , to June 30, 2015 , among patients with nonvalvular atrial fibrillation diagnoses who were receiving rivaroxaban. The information included in the analyses for this study cohort was identified through relevant International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes and Common Procedure Terminology and Healthcare Common Procedure Coding System procedure codes that were listed in any available procedure field within any medical encounter record. The ICD-9 code 427.31 was used to identify patients with atrial fibrillation, and a separate set of diagnosis and procedure codes was used to further distinguish nonvalvular atrial fibrillation patients.
All patients meeting the definition for nonvalvular atrial fibrillation were included, regardless of incident or prevalent rivaroxaban usage, as long as the patient was identified as having nonvalvular atrial fibrillation before or concurrent with rivaroxaban usage. Patients were evaluated for major bleeding during the study period or censored at the earliest occurrence of any of 4 events: a major bleeding event, death, loss of Military Health System eligibility, or end of study.
Outcome Measures
The primary outcome of interest was major bleeding, as defined by the Cunningham algorithm. 17 Cunningham et al 17 developed a validated database algorithm using administrative data for identification of major bleeding events that result in a hospitalization. Per the algorithm, bleeding events determined to be trauma related were excluded. The Cunningham algorithm identifies bleedingrelated hospitalizations from the primary discharge diagnosis, with the types of major bleeding events considered including gastrointestinal bleeding, hemorrhagic strokes, other intracranial bleeding events, and bleeding at other sites. The use of bleeding diagnoses showed a positive predictive value of 89% to 99% in the validation study by Cunningham et al, 17 and this algorithm has been used in other clinical studies to identify serious bleeding events. 16, [18] [19] [20] [21] [22] [23] [24] [25] Although the Cunningham algorithm is a comprehensive and validated case-finding tool, the definition for major bleeding in this study is not an exact match with the clinical trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation [ROCKET-AF]) definition because the algorithm is applied retrospectively and relies on the information available in the electronic medical record. As a comparison, the clinical trial definition of major bleeding was defined as clinically overt bleeding associated with a decrease in hemoglobin level of 2 g/dL or more, or a transfusion of 2 or more units of packed RBCs or whole blood, or major bleeding in a critical site, or a fatal outcome. 26 Major bleeding events were included if they occurred anytime during rivaroxaban exposure plus 7 days postdiscontinuation. The drug exposure period for patients was captured from the initiation date of rivaroxaban therapy until its discontinuation. For patients who experienced a major bleeding event, data were collected on major bleeding management, fatal outcomes, and discharge status.
Primary Data Analysis
Descriptive statistics are presented on patient demographics, comorbidities, rivaroxaban usage, hospitalization and bleeding-event management data, bleeding-event characteristics, and outcomes. Because the database contained limited data on smoking, alcohol use, race, and body mass index, these variables are not presented.
Categorical variables were summarized with counts and proportions. Mean values, along with SD, were calculated for continuous variables. No a priori hypothesis testing was planned or performed.
The incidence rates of major bleeding plus 95% confidence intervals (CIs) were calculated using a persontime approach: the number of patients with a first episode of major bleeding divided by the exposure time at risk, reported in person-centuries. Subsequent major bleeding events in patients experiencing multiple bleeding events were not included in the incidence rate calculations or related analyses. Baseline characteristics of the study population were stratified and evaluated by CHA 2 DS 2 -VASc scores and major bleeding status (major bleeding versus no major bleeding).
CHA 2 DS 2 -VASc scores were calculated for each study patient, using the schema presented in Table 1 , with age defined at bleeding for major bleeding cases and at the end of study participation for patients without major bleeding. Major bleeding incidence rates were also calculated by bleeding site and for each CHA 2 DS 2 -VASc score category.
Comorbidities were defined within a 6-month period before the date of bleeding event for major bleeding cases and at the end of study participation for patients without major bleeding. The major bleeding incidence rate was studied by score category (0 to 5), as well as by each component of CHA 2 DS 2 -VASc scoring.
Data captured for this study were subject to multiple quality control measures. The Department of Defense houses all of the queryable data sources within the Military Health System Data Repository. Incoming records transmitted to the repository are verified to be constructed in a standardized format respective to the data source, and all data elements are inspected for acceptable formats and to ensure that they are devoid of improbable values. Records that meet the minimum standards are then processed according to a set of published business rules and transformed into standardized data sets.
The Military Health System Data Repository is a SAScomputable environment, and all data sets within the repository are linked by a common, unique patient identifier. Two SAS programmers worked in parallel to independently draft code necessary to query and analyze all data pertinent to this study.
This postmarketing safety surveillance study was part of a postmarketing commitment, which was funded by Janssen Scientific Affairs, LLC and Bayer HealthCare. The study protocol, including the ascertainment method of major bleeding events, was reviewed and approved by the Food and Drug Administration before its finalization. The research data were derived from an approved Naval Medical Center, Portsmouth, Virginia institutional review board protocol, and the research was conducted in compliance with federal and state laws, including the Health Insurance Portability and Accountability Act of 1996.
Health ResearchTx, LLC carried out all analyses with SAS (version 9.2; SAS Institute, Inc., Cary, NC).
RESULTS
A total of 44,793 rivaroxaban users with nonvalvular atrial fibrillation were identified during the study interval. During this 2.5-year period, 1,352 major bleeding events in 1,293 patients were identified. The overall major bleeding incidence rate, based on a patient's first major bleeding event, was 2.84 (95% CI 2.69 to 3.00) per 100 person-years. Table 2 shows baseline characteristics of the study cohort stratified by CHA 2 DS 2 -VASc score category and major bleeding status. Across the entire study cohort, patients with major bleeding had a median CHA 2 DS 2 -VASc score of 4 (quartile 1, quartile 3: 4, 5) compared with 3 (quartile 1, quartile 3: 2, 5) among those without major bleeding. Consistent with nonvalvular atrial fibrillation guideline recommendations, the majority of patients (90.7%) receiving rivaroxaban had a CHA 2 DS 2 -VASc score of 2 or greater. Patients with a CHA 2 DS 2 -VASc score less than 2 (<10% of the total cohort) represented a disproportionately male population, with less than 10% women. This is not unexpected because female patients with one additional risk factor would be classified as having a CHA 2 DS 2 -VASc greater than or equal to 2. However, it is not entirely clear why these patients with low risk received rivaroxaban therapy.
Characteristics of Study Subjects
The highest proportion of the study population was patients with a CHA 2 DS 2 -VASc score greater than 4 (n¼11,760; 26.3%). Overall, 72% of all patients had a MB, Major bleeding; CHD, coronary heart disease; VTE, venous thromboembolism; CHF-LVD, congestive heart failure-left ventricular dysfunction. *Age is at MB or at end of study participation for patients without major bleeding. † Individual variables of interest identified within the 6-month period before MB for cases and within the 6-month period before the end of the study period for non-MB patients.
score of 3 or higher, and nearly half of the major bleeding events occurred in those with a score of 5 or greater (n¼635). For patients with a CHA 2 DS 2 -VASc score greater than or equal to 2 (considered the "high" category), mean age increased as scores increased, with an average age of 80 years for those with the highest scores. The sex distribution was predominantly male in the lower score categories, changing to predominantly female in the score categories of 5 and above. Compared to patients without major bleeding, those with major bleeding tended to be older, with higher prevalence of all recorded comorbidities. The distribution of rivaroxaban dosing showed that 20 mg (the dose recommended for nonvalvular atrial fibrillation patients with normal renal function per the label 27 ) was the predominant dose across all CHA 2 DS 2 -VASc score categories ( Table 3 ). The proportion of patients receiving a 15-mg dose (the dose recommended for nonvalvular atrial fibrillation patients with impaired renal function per the label 27 ) increased as scores increased, which coincides with the presence of increasing renal disease and other comorbidities. A small percentage of patients received the 10-mg dose of rivaroxaban. Although this dosing is consistent with the postoperative venous thromboembolism prophylaxis recommendation of rivaroxaban, the reasons for the administration of this dose in a nonvalvular atrial fibrillation cohort are unclear.
Major Bleeding Rates and Characteristics by CHA 2 DS 2 -VASc Scores Table 3 shows the incidence of major bleeding stratified by CHA 2 DS 2 -VASc score category. A monotonically increasing relationship was noted between CHA 2 DS 2 -VASc scores and the incidence rate of major bleeding. The rate of major bleeding among patients with a score of zero was 0.30 (95% CI 0.08 to 1.20) , with the rate continually increasing as the CHA 2 DS 2 -VASc score increased, reaching a rate of 5.40 (95% CI 5.00 to 5.84) per 100 person-years in those with a score of 5 or greater. The major bleeding rate, stratified by bleeding location, was highest for gastrointestinal bleeding events across all CHA 2 DS 2 -VASc score categories (Table 3) .
Overall, 41 patients had a major bleeding-related fatal outcome. Mortality risk generally had a positive relationship with CHA 2 DS 2 -VASc scores (Table 3) , with higher scores indicating higher mortality rates. The mean age at death by CHA 2 DS 2 -VASc score was 60 (SD 0), 67 (SD 0), 75.8 (SD 6.4), 75.7 (SD 8.4), 81.5 (SD 5.7), and 84.5 (SD 4.2) years, for scores 0, 1, 2, 3, 4, and greater than or equal to 5, respectively. Within the entire cohort, mortality associated with a hospitalization for major bleeding was experienced at a rate of 0.09 (95% CI 0.07 to 0.12) and a case-fatality rate of 3.2%.
Major bleeding incidence rates were also evaluated for the presence or absence of each CHA 2 DS 2 -VASc component. Results of key findings from these analyses are displayed in Table 4 and the Figure. The CHA 2 DS 2 -VASc subgroup with the highest incidence of major bleeding was those with vascular disease (major bleeding rate was 5.69 [95% CI 5.18 to 6.24] per 100 person-years), followed by those with a history of stroke, transient ischemic attack, or venous thromboembolism (major bleeding rate of 5.68 [95% CI 5.01 to 6.43] per 100 person-years).
The subgroup with the highest incidence of gastrointestinal bleeding was those with vascular disease, who had a major bleeding rate of 5.04 (95% CI 4.56 to 5.56) per 100 person-years (Figure and Table E1 [available online at htttp://www.annemergmed.com]). The highest incidence of intracranial hemorrhage was in the subgroup of patients with a history of stroke, transient ischemic attack, or venous thromboembolism, with an incidence of 0.60 (95% CI 0.41 to 0.88) per 100 person-years. Among patients who experienced a fatal outcome during their hospitalization for major bleeding, the highest mortality incidence was in the subgroup with a history of stroke, transient ischemic attack, or venous thromboembolism, at 0.21 (95% CI 0.11 to 0.39) per 100 person-years (Table 4) , a case-fatality rate of 3.6%.
LIMITATIONS
The current study has limitations. This retrospective analysis was based on data points that were originally collected for electronic medical record and accounting or claims purposes, rather than research. Additionally, pharmacy records captured the drug-dispensing information rather than the actual administration of the drug, and connecting the use of rivaroxaban to a bleeding event establishes only a temporal association rather than a causal relationship. Although major bleeding might be underreported because of limitations of the databases, there is also the possibility of capturing false positives, eg, minor or clinically irrelevant bleeding events. 16 Additionally, as with other database studies, there is a data lag associated with data processing and releasing for analyses that is estimated to affect the capture of only a small number of major bleeding cases, so there should be no material influence on the overall study findings.
Also, although it might have been useful to explore comparisons between the Hypertension, Abnormal Renal/ Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly (>65 years), Drugs/Alcohol Concomitantly (HAS-BLED) score and the CHA 2 DS 2 -VASc scores to compare assessments of bleeding risk, international normalized ratio data were not available in our data set and thus prevented calculation of HAS-BLED scores.
Finally, major bleeding in this study is not an exact match with that in clinical trials because the algorithm was applied retrospectively and relied on information available in the database. However, the rates and pattern of major bleeding in this study are generally consistent with the findings from the clinical trial for rivaroxaban. For example, the reported rates of rivaroxaban associated major bleeding were 3.6 per 100 person-years in patients with nonvalvular atrial fibrillation in the ROCKET-AF trial 26,28 and 2.84 per 100 person-years in this ongoing postmarketing pharmacovigilance study. In addition, these studies demonstrated consistency that gastrointestinal bleeding is the most common form of major bleeding event, and death associated with gastrointestinal bleeding is not common (ie, approximately 0.1 per 100 person-years).
DISCUSSION
Numerous recent studies have validated the predictive capabilities of CHA 2 DS 2 -VASc for assessing risk of stroke, 1, [29] [30] [31] [32] consistently demonstrating that higher CHA 2 DS 2 -VASc scores are associated with greater risk for stroke. This is in conflict with studies that suggest that clinicians may withhold anticoagulation therapy from patients with higher CHA 2 DS 2 -VASc scores because of a concern regarding increased risk of bleeding. Balancing this risk-benefit trade-off, particularly in high-risk patients, represents a clinical challenge. Our current analysis showed a strong relationship between CHA 2 DS 2 -VASc scores and the risk of major bleeding in rivaroxaban users with nonvalvular atrial fibrillation; as CHA 2 DS 2 -VASc scores increased, so did the incidence of major bleeding.
Our findings are particularly relevant in the context of the relationship between CHA 2 DS 2 -VASc score and the risk of ischemic stroke, as demonstrated in other studies, 33 and this importance could be reflected by 2 aspects: (1) for any given risk score, the risk of stroke may exceed the risk of major bleeding, which is a trade-off for prophylactic antithrombotic therapy; and (2) from a benefit-risk perspective, stroke represents irreversible harms, whereas bleeding is often considered transient and manageable. 34, 35 Lip et al 33 determined that CHA 2 DS 2 -VASc scores are associated with a stepwise increase in the estimated rates of thromboembolism. The difference between their estimated stroke rates by CHA 2 DS 2 -VASc scores and that of the incidence of major bleeding by CHA 2 DS 2 -VASc score in our study suggests that the net clinical benefit (risk of bleeding mitigated by greater risk of stroke) of anticoagulation with rivaroxaban actually increases as CHA 2 DS 2 -VASc score increases. For example, among patients with the highest number of risk factors (in the 5 score category), the Lip et al 33 analysis demonstrated that the highest estimated overall (weighted) risk of thromboembolism or stroke was 8.1% per year compared with the highest major bleeding rate of 5.40 (95% CI 5.00 to 5.84) per 100 person-years in this study population. This finding implies that, despite an increasing risk of bleeding associated with increasing CHA 2 DS 2 -VASc scores, the risk of stroke is likely much higher, suggesting that the net clinical benefit may still favor anticoagulation, even among patients within the highest risk categories. Although we caution against indirect comparisons across studies, these empirical data may be informative and provide a basic framework for physicians to evaluate and make treatment decisions.
Although both stroke and major bleeding incidence increase with higher CHA 2 DS 2 -VASc scores, the rate of increase is greatest for estimated stroke risk. We did not calculate HAS-BLED 36 scores for this analysis because an approximation of bleeding risk is less accurate than using the actual bleeding rates that were observed for the study cohort. Although our results in regard to the relationship between CHA 2 DS 2 -VASc scores and bleeding are not meant to replace existing bleeding risk metrics, we propose that using CHA 2 DS 2 -VASc scores as a possible indicator of bleeding risk is complementary to other risk measures.
Our report shows that major bleeding was experienced by a small proportion of rivaroxaban patients with nonvalvular atrial fibrillation, and among known high-risk Table E1 , available online at http://www.annemergmed.com, for the full complement of data, including CIs.)
populations the highest rate of major bleeding by CHA 2 DS 2 -VASc component was 5.69 (95% CI 5.18 to 6.24) per 100 person-years for patients with vascular disease. As shown in this study and noted in previous studies of rivaroxaban, gastrointestinal bleeding events are the most common source of major bleeding, but the potential for mortality is low. Conversely, although intracranial hemorrhage is rare (eg, moderate-risk category) or uncommon (eg, high-risk category), it has a much higher association with mortality compared with gastrointestinal bleeding events. In this analysis, patients with previous stroke, transient ischemic attack, or venous thromboembolism represented the cohort who had the greatest incidence of intracranial hemorrhage and thus were at greater risk of mortality. In the setting of previous stroke, transient ischemic attack, or venous thromboembolism, physicians may balance individual bleeding risks and future stroke risk, although not undermining that this is the basic principle for the management of atrial fibrillation patients in any risk category. In summary, clinicians must balance the benefit of stroke prevention with the risk of bleeding when prescribing anticoagulant therapy. We report that in this cohort of nearly 45,000 nonvalvular atrial fibrillation patients receiving rivaroxaban therapy, the CHA 2 DS 2 -VASc score showed a strong relationship with major hemorrhage. Patients most likely to experience a major hemorrhage are also those with greater stroke risk and thus would potentially sustain greater benefit from anticoagulation than from its avoidance. Additional research may be warranted.
